2013 Fiscal Year Final Research Report
Development of molecular target therapy for EBV
| Project/Area Number |
23590134
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
NOGUCHI Kohji 慶應義塾大学, 薬学部, 准教授 (80291136)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | ウイルス / がん / EBV / 分子標的 |
|---|
| Research Abstract |
Epstein-Barr Virus (EBV) transforms human B lymphocytes into immortalized cells in vitro, and is associated with various malignancies in vivo. DNA-binding protein EBNA1 plays critical role for the viral episome maintenance and transactivates viral transforming genes in latently infected cells. Therefore, DNA-targeting agents that can disrupt the EBNA1-DNA interaction will offer novel functional inhibitors of EBNA1. Here, a synthetic pyrrole-imidazole polyamide bound adjacent to the EBNA1 recognition sequences located in the dyad symmetry element of oriP, and selectively inhibited EBNA1-oriP binding. This polyamide inhibited EBV-mediated B-cell immortalization. These results suggest that EBNA1 functions will be an attractive pharmacological target for EBV-associated diseases.
|
